Palatin Technologies, Inc. (PTNT)
OTCMKTS · Delayed Price · Currency is USD
8.59
-0.16 (-1.85%)
At close: Sep 11, 2025
Palatin Technologies Revenue
Palatin Technologies had revenue of $350.00K in the twelve months ending March 31, 2025, down -94.07% year-over-year. In the fiscal year ending June 30, 2024, Palatin Technologies had annual revenue of $4.49M, down -7.49%.
Revenue (ttm)
350.00K
Revenue Growth
-94.07%
P/S Ratio
23.86
Revenue / Employee
11.67K
Employees
30
Market Cap
8.35M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 4.49M | -363.59K | -7.49% |
| Jun 30, 2023 | 4.85M | 3.39M | 230.53% |
| Jun 30, 2022 | 1.47M | 1.66M | -878.62% |
| Jun 30, 2021 | -188.60K | -306.59K | -259.84% |
| Jun 30, 2020 | 117.99K | -60.18M | -99.80% |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 105.45M |
| Tian'an Technology Group | 2.12M |
| Glass House Brands | 221.55M |
| Northwest Biotherapeutics | 1.09M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.17M |
| Global Cord Blood | 196.10M |
Palatin Technologies News
- 24 days ago - Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases - GlobeNewsWire
- 4 weeks ago - Palatin Announces 1-for-50 Reverse Stock Split - PRNewsWire
- 2 months ago - Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity - PRNewsWire
- 4 months ago - Palatin Technologies, Inc. (PTN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update - PRNewsWire
- 4 months ago - Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 - PRNewsWire
- 4 months ago - Palatin Technologies Announces Closing of Reduced Public Offering - PRNewsWire
- 4 months ago - Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice - PRNewsWire